GlassScriptPhysician profile
Devin Rhyman
NPI 1881061422
$10,488.60
in general payments reported to CMS, 2019-2025
62 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,434 · 2022: $2,081 · 2023: $2,156 · 2024: $1,796 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,973.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,595.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,541.69 | 2021-2025 | |
| Lilly USA, LLC | $726.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $638.03 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $473.17 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.33 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $381.31 | 2021-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $306.77 | 2021-2025 | Verquvo, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $290.05 | 2022 | |
| Xeris Pharmaceuticals, INC. | $289.56 | 2024-2025 | Recorlev |
| Axsome Therapeutics, INC. | $242.98 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $235.95 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $230.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $193.91 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $185.26 | 2021-2025 | Farxiga, Breztri, Airsupra |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Rhyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.